Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Prostate Cancer Therapeutics Market

Prostate Cancer Therapeutics Market Share

Report ID: GMI10189
Published Date: Jul 2024
Report Format: PDF

Download Free Sample

Prostate Cancer Therapeutics Market Share

The market is characterized by a diverse range of treatments aimed at managing various stages of prostate cancer. Hormonal therapies like androgen deprivation therapy (ADT) and androgen receptor inhibitors (ARIs) dominate, addressing hormone-sensitive and castration-resistant forms. Chemotherapy, immunotherapy, and targeted therapies such as PARP inhibitors are also significant. Market dynamics are driven by ongoing research, regulatory developments, and advancements in personalized medicine. North America and Europe lead in market share due to advanced healthcare infrastructures and high disease prevalence, while emerging regions show growing potential with expanding healthcare access and increasing adoption of innovative therapies.

Prostate Cancer Therapeutics Market Companies

Prominent players operating in the prostate cancer therapeutics industry include:

Astellas Pharma Inc.
AstraZeneca Plc
Bayer AG
Dendreon Pharmaceuticals LLC.
Exelixis, Inc
Ferring B.V.
GlaxoSmithKline Plc
Ipsen Pharma
Johnson & Johnson
Novartis AG
Pfizer Inc.
Sanofi S.A
Sumitomo Pharma America, Inc.
Takeda Pharmaceutical Company Limited
Tolmar Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Prostate cancer therapeutics industry size was USD 11.7 billion in 2023 and is projected to expand at 8.8% CAGR from 2024 to 2032, due the ongoing advancements in treatment modalities, and expanding pipeline of novel therapies.

The hormonal therapy segment in the prostate cancer therapeutics industry accounted for USD 8.1 billion in revenue in 2023, as it is effective in reducing levels of androgens (male hormones), such as testosterone.

The androgen receptor inhibitors drug class segment in the prostate cancer therapeutics industry accounted for 35% share in 2023 and is estimated to witness significant growth between 2024 and 2032, owing to their ability to provide therapeutic options to manage CRPC by targeting androgen receptor signaling pathways.

North America prostate cancer therapeutics industry recorded USD 4.6 billion in revenue in 2023 and is projected to grow at 8.4% CAGR from 2024 to 2032, led by the presence of advanced healthcare infrastructure, including well-equipped hospitals, specialized cancer centers, and comprehensive oncology care facilities.